Rituximab for intractable myasthenia gravis

Rituximab for intractable myasthenia gravis - Rituximab for myasthenia gravis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000016564

Enrollment

Registered

2015-02-23

Start date

2015-03-13

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

myasthenia gravis

Interventions

rituximab

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: intractable people with generalized myasthenia gravis

Exclusion criteria

Exclusion criteria: infant, child, pregnant woman

Design outcomes

Primary

Measure	Time frame
blood examination (lymphocyte, antibody titer), myasthenia symptoms, MG-ADL score	—

Countries

Japan

Contacts

Public ContactNaoko Matsui

Tokushima University Hospital Neurology

nao-mm@clin.med.tokushima-u.ac.jp088-633-7207

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026